Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOLSEEK-1: Golcadomide plus R-CHOP vs placebo plus R-CHOP in high-risk large B-cell lymphoma
2023-510178-15-00Phase 3Authorised
- Sponsor
- Celgene Corporation
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 36
01
Overview
Phase 3, randomised, double-blind trial in diffuse large B-cell lymphoma (DLBCL) comparing Golcadomide plus R-CHOP with Placebo plus R-CHOP (2 arms). Primary endpoint: Progression-free survival. Planned start Jul 2024; status: authorised.
02
Drugs
golcadomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2023-510178-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510178-15-00.